144 related articles for article (PubMed ID: 28549032)
1. Expression of Phosphoinositide 3-Kinase p110α and p110β Subunits and PIK3CA Mutation in Patients With Advanced Gastric Carcinoma.
Kim K; Lee HW
Appl Immunohistochem Mol Morphol; 2018; 26(10):740-748. PubMed ID: 28549032
[TBL] [Abstract][Full Text] [Related]
2. Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER
Hosford SR; Dillon LM; Bouley SJ; Rosati R; Yang W; Chen VS; Demidenko E; Morra RP; Miller TW
Clin Cancer Res; 2017 Jun; 23(11):2795-2805. PubMed ID: 27903677
[No Abstract] [Full Text] [Related]
3. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
Dornan GL; Burke JE
Front Immunol; 2018; 9():575. PubMed ID: 29616047
[TBL] [Abstract][Full Text] [Related]
4. Class I Phosphoinositide 3-Kinase
Mazloumi Gavgani F; Smith Arnesen V; Jacobsen RG; Krakstad C; Hoivik EA; Lewis AE
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544563
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of phosphoinositide 3-kinase p110α and p110β isoforms in non-small cell lung cancer.
Lee JS; Lee HW; Lee EH; Park MI; Lee JS; Kim MS; Kim SH; Kim TG; Nam HY; Hwang SW; Park JH
Int J Clin Exp Pathol; 2018; 11(3):1554-1561. PubMed ID: 31938253
[TBL] [Abstract][Full Text] [Related]
6. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.
Zhao JJ; Liu Z; Wang L; Shin E; Loda MF; Roberts TM
Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18443-8. PubMed ID: 16339315
[TBL] [Abstract][Full Text] [Related]
7. Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation.
Karlsson T; Krakstad C; Tangen IL; Hoivik EA; Pollock PM; Salvesen HB; Lewis AE
Oncotarget; 2017 Jan; 8(3):3881-3894. PubMed ID: 28002804
[TBL] [Abstract][Full Text] [Related]
8. Studies on the expression patterns of class I PI3K catalytic subunits and its prognostic significance in colorectal cancer.
Cui B; Tao J; Yang Y
Cell Biochem Biophys; 2012 Jan; 62(1):47-54. PubMed ID: 21910030
[TBL] [Abstract][Full Text] [Related]
9. p110α and p110β isoforms of PI3K are involved in protection against H
Singh P; Bano N; Hossain MM; Basit R; Dar MJ
Breast Cancer; 2019 May; 26(3):378-385. PubMed ID: 30499025
[TBL] [Abstract][Full Text] [Related]
10. The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type.
Utermark T; Schmit F; Lee SH; Gao X; Schaffhausen BS; Roberts TM
J Virol; 2014 Sep; 88(18):10673-9. PubMed ID: 24991009
[TBL] [Abstract][Full Text] [Related]
11. Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers.
Zhu Q; Youn H; Tang J; Tawfik O; Dennis K; Terranova PF; Du J; Raynal P; Thrasher JB; Li B
Oncogene; 2008 Jul; 27(33):4569-79. PubMed ID: 18372911
[TBL] [Abstract][Full Text] [Related]
12. PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer.
Carvalho S; Milanezi F; Costa JL; Amendoeira I; Schmitt F
Virchows Arch; 2010 Mar; 456(3):235-43. PubMed ID: 20130907
[TBL] [Abstract][Full Text] [Related]
13. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
14. PIK3CB/p110β is a selective survival factor for glioblastoma.
Pridham KJ; Le L; Guo S; Varghese RT; Algino S; Liang Y; Fajardin R; Rodgers CM; Simonds GR; Kelly DF; Sheng Z
Neuro Oncol; 2018 Mar; 20(4):494-505. PubMed ID: 29016844
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of GFP-Fusion p110α and p110β Isoforms of PI3K Signaling Pathway in Normal and Cancer Cells.
Singh P; Dar MS; Singh G; Jamwal G; Sharma PR; Ahmad M; Dar MJ
J Cell Biochem; 2016 Dec; 117(12):2864-2874. PubMed ID: 27167447
[TBL] [Abstract][Full Text] [Related]
16. P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse.
Iyengar S; Clear A; Bödör C; Maharaj L; Lee A; Calaminici M; Matthews J; Iqbal S; Auer R; Gribben J; Joel S
Blood; 2013 Mar; 121(12):2274-84. PubMed ID: 23341541
[TBL] [Abstract][Full Text] [Related]
17. Distinct epithelial-to-mesenchymal transitions induced by
Gjelaj E; Hamel PA
J Cell Sci; 2021 Feb; 134(4):. PubMed ID: 33526718
[TBL] [Abstract][Full Text] [Related]
18. Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.
Berenjeno IM; Guillermet-Guibert J; Pearce W; Gray A; Fleming S; Vanhaesebroeck B
Biochem J; 2012 Feb; 442(1):151-9. PubMed ID: 22150431
[TBL] [Abstract][Full Text] [Related]
19. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
Edgar KA; Wallin JJ; Berry M; Lee LB; Prior WW; Sampath D; Friedman LS; Belvin M
Cancer Res; 2010 Feb; 70(3):1164-72. PubMed ID: 20103642
[TBL] [Abstract][Full Text] [Related]
20. Over-expression of the p110beta but not p110alpha isoform of PI 3-kinase inhibits motility in breast cancer cells.
Yip SC; El-Sibai M; Hill KM; Wu H; Fu Z; Condeelis JS; Backer JM
Cell Motil Cytoskeleton; 2004 Nov; 59(3):180-8. PubMed ID: 15468162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
